BofA raised the firm’s price target on Alkermes (ALKS) to $34 from $33 and keeps a Neutral rating on the shares. The company’s Q4 report and FY25 guidance “offered no major surprises,” the analyst tells investors. Data in the second half for ALKS2680 in narcolepsy is the “key company catalyst” and the next quarterly update may provide a more detailed timeline for data readouts of the two ongoing studies, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes: Stability with Limited Upside Amid Program Expectations and Competitive Pressures
- Alkermes plc Reports Strong 2024 Financial Results
- Alkermes’ Strong Financial Performance and Future Growth Prospects Drive Buy Rating
- Alkermes sees FY25 revenue $1.340B-$1.430B, consensus $1.41B
- Alkermes reports Q4 non-GAAP EPS $1.05, consensus 76c